Published in PLoS One on February 25, 2016
HIV Infection and Bone Abnormalities. Open Orthop J (2017) 0.75
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser (1994) 17.37
HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med (2011) 6.30
Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA (2009) 5.52
Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys (2008) 3.61
Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA (2004) 3.35
Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res (2004) 2.63
Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res (2005) 2.49
Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis (2009) 2.24
Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis (2010) 2.20
Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis (2007) 2.16
Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection. AIDS (1992) 1.94
Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev (2013) 1.68
Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine (2004) 1.64
Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone (2008) 1.64
Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis (2008) 1.51
The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther (2006) 1.34
Loss of CD28 expression on T lymphocytes: a marker of replicative senescence. Dev Comp Immunol (1998) 1.31
Aging, inflammation, and HIV infection. Top Antivir Med (2012) 1.25
RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med (2009) 1.17
T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosis. PLoS One (2012) 1.12
Vascular calcification and osteoporosis--the nature of the nexus. J Clin Endocrinol Metab (2004) 1.07
Relationships between calcified atherosclerotic plaque and bone mineral density in African Americans with type 2 diabetes. J Bone Miner Res (2011) 1.06
Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int (2008) 1.06
Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr (2013) 1.05
Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol (2008) 1.03
Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. Intern Emerg Med (2010) 1.02
The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection. Stroke (2007) 1.01
Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø Study. J Thromb Haemost (2011) 0.99
Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy. J Acquir Immune Defic Syndr (2014) 0.99
Bone morphogenetic protein 7 (BMP7) gene polymorphisms are associated with inverse relationships between vascular calcification and BMD: the Diabetes Heart Study. J Bone Miner Res (2009) 0.96
Osteoprotegerin, RANK, RANKL. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2001) 0.93
Mechanisms of immunosenescence: lessons from models of accelerated immune aging. Ann N Y Acad Sci (2012) 0.93
Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy. J Infect (2011) 0.92
HIV and aging: emerging research issues. Curr Opin HIV AIDS (2014) 0.91
Role of biomarkers in predicting CVD risk in the setting of HIV infection? Curr Opin HIV AIDS (2010) 0.88
Normal human primary CD4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro. Lab Invest (2007) 0.88
Receptor activator of nuclear factor-κB ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients. J Acquir Immune Defic Syndr (2012) 0.88
Correlation between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab (2014) 0.84
Clinical factors associated with carotid plaque and intima-medial thickness in HIV-infected patients. Yonsei Med J (2013) 0.79
Invariant natural killer T (iNKT) cells in HAART-treated, HIV-positive patients with bone and cardiovascular impairment. PLoS One (2014) 0.78
Immune activation, immunosenescence, and osteoprotegerin as markers of endothelial dysfunction in subclinical HIV-associated atherosclerosis. Mediators Inflamm (2014) 0.77
HIV infection and osteoporosis. Bonekey Rep (2015) 0.77
Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection. AIDS Rev (2014) 0.76